Aimmune ’s Phase III trial commences enrolment to study AR101 for peanut allergy

Aimmune Therapeutics has commenced patient enrolment in a Phase III RAMSES (ARC007) clinical trial of AR101 to treat peanut allergy.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news